Visgenx Company
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
Technology:
Regenerative Medicine
Industry:
Biotechnology, Medical, Therapeutics
Headquarters:
San Diego, California, United States
Founded Date:
2018-01-01
Employees Number:
1-10
Investors Number:
2
Total Funding:
$2.3M
Last Funding Type:
Seed
Register and Claim Ownership